Jeena Sikho

Which are the latest news on Jeena Sikho?

Why is Jeena Sikho Lifecare Ltd falling/rising?

As of 05-Sep, Jeena Sikho Lifecare Ltd's stock price is rising to Rs 516.70, driven by strong relative performance and increased investor interest, despite a significant decline of -33.68% over the past year. The company’s net-debt free status and healthy growth metrics contribute to current positive momentum, though risks remain due to past underperformance.

As of 05-Sep, Jeena Sikho Lifecare Ltd's stock price is rising, currently at Rs 516.70, reflecting an increase of Rs 14.85 or 2.96%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 4.67% today, indicating strong relative performance. Additionally, the stock reached an intraday high of Rs 529.8, which is a 5.57% increase from its previous price, suggesting positive momentum in trading.<BR><BR>Investor participation has also seen a notable rise, with delivery volume increasing by 74.99% compared to the 5-day average, indicating growing interest among retail investors. Furthermore, the company is net-debt free and has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 42.60% and operating profit rising by 83.75%. The positive results over the last four consecutive quarters, including higher net sales and profit after tax, further bolster investor confidence.<BR><BR>However, it is important to note that while the stock is currently rising, it has experienced significant declines over the past year, with a return of -33.68%. This long-term underperformance, coupled with a decrease in institutional investor participation, may pose risks to sustained growth. Nonetheless, the current positive indicators suggest a temporary upward trend in the stock price.

Who are in the management team of Jeena Sikho?

The management team of Jeena Sikho includes Executive Director Manish Grover, Whole-time Director Bhavna Grover, Non-Executive Directors Shreya Grover, Suraj Prakash Choudhary, Karan Vir Bindra, and Company Secretary Nikita Juneja, who collectively oversee the company's strategic direction and compliance.

The management team of Jeena Sikho includes the following members:<BR><BR>1. **Manish Grover** - Executive Director, with a remuneration of INR 2.4 crore.<BR>2. **Bhavna Grover** - Whole-time Director, earning INR 1.8 crore.<BR>3. **Shreya Grover** - Non-Executive Director, with no remuneration.<BR>4. **Suraj Prakash Choudhary** - Non-Executive Director, earning INR 1.44 lakhs.<BR>5. **Karan Vir Bindra** - Non-Executive Director, also earning INR 1.44 lakhs.<BR>6. **Nikita Juneja** - Company Secretary & Compliance Officer, with a remuneration of INR 3.0 lakhs.<BR><BR>This team is responsible for guiding the company's strategic direction and ensuring compliance with regulations.

What does Jeena Sikho do?

Jeena Sikho Lifecare Ltd is a small-cap Ayurvedic healthcare company, incorporated in 2017 and converted to a public company in 2021. As of June 2026, it reported net sales of 224 Cr and a net profit of 66 Cr, with a market cap of INR 6,352 Cr.

Overview:<BR>Jeena Sikho Lifecare Ltd is a renowned Ayurvedic healthcare company operating in the hospital industry and classified as a small-cap entity.<BR><BR>History:<BR>The company was originally incorporated as "Jeena Sikho Lifecare Private Limited" in 2017 and later converted to a public limited company, adopting the name "Jeena Sikho Lifecare Limited" in July 2021. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 224 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 66 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 6,352 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 27.00<BR>- Industry P/E: 67<BR>- Dividend Yield: 0.21%<BR>- Debt Equity: -0.16<BR>- Return on Equity: 50.61%<BR>- Price to Book: 13.61<BR><BR>Contact Details:<BR>No Company Details Available.

Who are the peers of the Jeena Sikho?

Peers of Jeena Sikho include Health.Global, Jupiter Life Lin, Yatharth Hospital, Kovai Medical, Artemis Medicare, Indraprastha Medical, Dr. Agarwal's Eye, KMC Specialty, and Shalby. Jeena Sikho shows excellent growth but has the lowest 1-year return among its peers at -27.85%.

Peers: The peers of Jeena Sikho are Health.Global, Jupiter Life Lin, Yatharth Hospit., Kovai Medical, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, and Shalby.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jupiter Life Lin and Kovai Medical, while Average management risk is found at Health.Global, Jeena Sikho, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, and the rest. Below Average management risk is noted at Yatharth Hospit. and Shalby. For Growth, Excellent growth is seen at Jeena Sikho, while Good growth is observed at Health.Global, Artemis Medicare, Indrapr.Medical, and the rest. Average growth is found at Yatharth Hospit. and Kovai Medical, while Below Average growth is noted at Jupiter Life Lin and Shalby. In terms of Capital Structure, Excellent capital structure is present at Jupiter Life Lin, Yatharth Hospit., KMC Speciality, and the rest, while Good capital structure is seen at Kovai Medical, Artemis Medicare, and the rest. Below Average capital structure is noted at Health.Global and Dr Agarwal's Eye.<BR><BR>Return Snapshot: The peer with the highest 1-year return is KMC Speciality at 97.77%, while Jeena Sikho has the lowest at -27.85%. This indicates that Jeena Sikho's performance is significantly lower than its peers. Additionally, Health.Global, Jupiter Life Lin, Yatharth Hospit., Kovai Medical, Indrapr.Medical, and Shalby have negative six-month returns.

How big is Jeena Sikho?

As of 31st August, Jeena Sikho Lifecare Ltd has a market capitalization of 6,352.00 Cr, with recent Net Sales of 851.48 Cr and a Net Profit of 236.49 Cr. Shareholder's Funds are 125.80 Cr and Total Assets amount to 150.59 Cr as of March 2023.

As of 31st August, Jeena Sikho Lifecare Ltd has a market capitalization of 6,352.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Jeena Sikho reported Net Sales of 851.48 Cr and a Net Profit of 236.49 Cr.<BR><BR>The latest annual period for the balance sheet is March 2023, with Shareholder's Funds amounting to 125.80 Cr and Total Assets of 150.59 Cr.

Should I buy, sell or hold Jeena Sikho Lifecare Ltd?

When is the next results date for Jeena Sikho Lifecare Ltd?

The next results date for Jeena Sikho Lifecare Ltd is 07 August 2026.

The next results date for Jeena Sikho Lifecare Ltd is scheduled for 07 August 2026.

Are Jeena Sikho Lifecare Ltd latest results good or bad?

Jeena Sikho Lifecare Ltd's latest results show strong year-on-year growth, with a 78.10% increase in net profit and a 54.79% rise in revenue. However, quarterly performance is concerning, with declines in both net profit and revenue, along with reduced profit margins, indicating potential challenges ahead.

The latest results for Jeena Sikho Lifecare Ltd present a mixed picture. On one hand, the company reported a significant year-on-year growth, with net profit increasing by 78.10% to ₹45.13 crore and revenue rising by 54.79% to ₹215.55 crore. This indicates strong annual performance and robust sales growth.<BR><BR>However, the quarterly results show concerning trends. Compared to the previous quarter, both net profit and revenue declined, with net profit falling by 32.30% and revenue decreasing by 2.77%. Additionally, the profit after tax margin dropped sharply from 30.04% to 20.91%, reflecting rising operational pressures. The operating margin also contracted significantly, indicating potential challenges in maintaining profitability.<BR><BR>Overall, while the company demonstrates strong long-term growth potential and exceptional return on equity, the recent quarterly performance raises questions about sustainability and could be seen as a warning sign for investors. Thus, the results can be characterized as good in terms of year-on-year growth, but bad when considering the sequential decline and margin compression.

Is Jeena Sikho technically bullish or bearish?

As of November 25, 2025, Jeena Sikho's trend has shifted to sideways, indicating a neutral stance with mixed signals from key indicators, including a mildly bearish outlook from Dow Theory and a mildly bullish trend in On-Balance Volume.

As of 25 November 2025, the technical trend for Jeena Sikho has changed from mildly bearish to sideways. The current stance is neutral, reflecting a lack of strong directional movement. Key indicators include a mildly bearish outlook from Dow Theory on the weekly timeframe, while the On-Balance Volume (OBV) shows a mildly bullish trend on the weekly basis. The MACD, RSI, and other indicators do not provide clear signals at this time. Overall, the stock's recent performance shows a slight gain over the past week, contrasting with a decline over the past month.

How has been the historical performance of Jeena Sikho?

Jeena Sikho experienced significant growth from March 2022 to March 2023, with net sales increasing to 204.75 Cr from 146.55 Cr, and profit after tax rising to 33.52 Cr from 11.19 Cr, reflecting strong improvements in operating profit margins and overall financial performance. Total assets also grew to 150.59 Cr, while cash flow showed a positive turnaround.

Answer:<BR>The historical performance of Jeena Sikho shows significant growth in various financial metrics from March 2022 to March 2023.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2023, Jeena Sikho reported net sales of 204.75 Cr, a notable increase from 146.55 Cr in the previous year. Total operating income mirrored this growth, reaching 204.75 Cr compared to 146.55 Cr in March 2022. The total expenditure, excluding depreciation, rose to 159.15 Cr from 128.50 Cr, while operating profit (PBDIT) surged to 48.20 Cr from 19.54 Cr, indicating a robust operating profit margin improvement from 12.32% to 22.27%. Profit before tax also saw a substantial rise to 44.29 Cr from 15.09 Cr, leading to a profit after tax of 33.52 Cr, up from 11.19 Cr, resulting in a PAT margin increase from 7.64% to 16.37%. The company's total assets grew to 150.59 Cr from 61.54 Cr, with total liabilities increasing to 150.59 Cr from 61.54 Cr. Cash flow from operating activities decreased slightly to 14.00 Cr from 16.00 Cr, but net cash inflow improved significantly to 29.00 Cr from a net outflow of 6.00 Cr, reflecting a strong closing cash position of 31.00 Cr compared to 2.00 Cr the previous year. Overall, Jeena Sikho demonstrated a strong upward trend in financial performance across key metrics.

Who are the top shareholders of the Jeena Sikho?

The top shareholders of Jeena Sikho include Manish Grover with 63.27%, Oregano Life Private Limited at 5.8%, and 12 foreign institutional investors holding a combined 5.91%. Individual investors own 17.05%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Jeena Sikho include the promoters, with Manish Grover holding the highest share at 63.27%. Additionally, Oregano Life Private Limited is the largest public shareholder, owning 5.8%. The company also has 12 foreign institutional investors (FIIs) that collectively hold 5.91% of the shares, while individual investors account for 17.05% of the holdings. There are no pledged promoter holdings, and no mutual funds currently hold shares in the company.

Is Jeena Sikho overvalued or undervalued?

As of May 19, 2025, Jeena Sikho is considered very expensive with a PE ratio of 61.03 and high valuation metrics, despite outperforming the Sensex with a 102.02% return over the past year, indicating it is overvalued compared to industry norms and some competitors.

As of 19 May 2025, the valuation grade for Jeena Sikho has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 61.03, a Price to Book Value of 28.80, and an EV to EBITDA ratio of 43.82, all of which are considerably high compared to industry norms. <BR><BR>In comparison to its peers, Max Healthcare Institute Ltd. has a PE ratio of 100.29 and an EV to EBITDA of 62.71, while Apollo Hospitals Enterprise Ltd. shows a PE of 69.03 and an EV to EBITDA of 34.71, indicating that Jeena Sikho, despite its high ratios, is still less expensive than some of its competitors. Notably, Jeena Sikho has outperformed the Sensex over the past year with a return of 102.02%, compared to the Sensex's 7.86%, but this strong performance does not justify its current valuation levels.

What is the bonus history of the Jeena Sikho?

Jeena Sikho Lifecare Ltd has announced a bonus issue of 4:5, with an ex-date of November 2, 2023. Shareholders will receive four additional shares for every five shares held as of the record date.

Jeena Sikho Lifecare Ltd recently announced a bonus issue with a ratio of 4:5, and the ex-date for this bonus is set for November 2, 2023. This means that shareholders will receive four additional shares for every five shares they hold as of the record date. If you have any more questions about the company or its financial activities, feel free to ask!

Has Jeena Sikho declared dividend?

Jeena Sikho Lifecare Ltd has declared a 41% dividend, amounting to 4.1 per share, with an ex-date of August 20, 2024. While the company has shown significant long-term returns, recent performance has been mixed, with a total return of -3.85% over the last six months.

Jeena Sikho Lifecare Ltd has declared a 41% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 41%<BR>- Amount per share: 4.1<BR>- Ex-date: 20 Aug 24<BR><BR>Dividend Yield: 0.18%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -3.85%, with a dividend return of 0%, resulting in a total return of -3.85%.<BR><BR>Over the past year, the price return was 113.33%, with a dividend return of 0.39%, leading to a total return of 113.72%.<BR><BR>In the two-year period, the price return was 743.87%, with a dividend return of 2.35%, culminating in a total return of 746.22%.<BR><BR>For the three-year period, the price return was 2643.14%, with a dividend return of 8.10%, resulting in a total return of 2651.24%.<BR><BR>In the four-year period, there was no price return and no dividend return, leading to a total return of 0.0%.<BR><BR>Over the five-year period, there was also no price return and no dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, Jeena Sikho Lifecare Ltd has declared a significant dividend, but the total returns over the last several periods show a mixed performance, with substantial gains in longer time frames but some recent volatility.